Cidara Therapeutics (CDTX) News Today $13.09 +0.09 (+0.69%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cidara Therapeutics to Participate in Two Upcoming November Investor ConferencesOctober 31 at 8:00 AM | globenewswire.comAnalyzing Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) & Cidara Therapeutics (NASDAQ:CDTX)October 31 at 4:25 AM | americanbankingnews.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 67,000 shares, a decrease of 20.0% from the September 30th total of 83,800 shares. Approximately 1.1% of the company's shares are short sold. Based on an average trading volume of 19,700 shares, the days-to-cover ratio is currently 3.4 days.October 29, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) versus PharmaCyte Biotech (OTCMKTS:PMCBD) Head-To-Head ContrastOctober 26, 2024 | americanbankingnews.comCidara Therapeutics (NASDAQ:CDTX) Earns Buy Rating from HC WainwrightOctober 25, 2024 | americanbankingnews.comPromising Results of CD388 Lead to Buy Rating for Cidara TherapeuticsOctober 23, 2024 | markets.businessinsider.comCidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $24.00 price target on shares of Cidara Therapeutics in a report on Tuesday.October 22, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below Fifty Day Moving Average - What's Next?Cidara Therapeutics (NASDAQ:CDTX) Stock Crosses Below Fifty Day Moving Average - Here's WhyOctober 22, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)October 4, 2024 | globenewswire.comCidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza ConferenceSeptember 25, 2024 | globenewswire.comCidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal InfluenzaSeptember 23, 2024 | globenewswire.comCidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease ExpertsSeptember 19, 2024 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Decrease in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 76,200 shares, a decrease of 23.2% from the August 15th total of 99,200 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily volume of 30,000 shares, the short-interest ratio is presently 2.5 days.September 17, 2024 | marketbeat.comCidara Therapeutics Buy Rating Affirmed on Strategic Focus and Promising CD388 Clinical DevelopmentsSeptember 16, 2024 | markets.businessinsider.comCidara Therapeutics (NASDAQ:CDTX) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $24.00 price objective on shares of Cidara Therapeutics in a report on Monday.September 16, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Sells $10,755.36 in StockSeptember 14, 2024 | insidertrades.comCidara axes 30% of staff to focus on flu prevention drugSeptember 14, 2024 | msn.comCidara Therapeutics (NASDAQ:CDTX) Upgraded to "Hold" at StockNews.comStockNews.com upgraded Cidara Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.September 13, 2024 | marketbeat.comCidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock DownSeptember 13, 2024 | markets.businessinsider.comCidara Therapeutics to Cut Workforce by 30%September 12, 2024 | marketwatch.comCidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388September 12, 2024 | globenewswire.comCidara to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comCidara Therapeutics Announces Appointment of Jim Beitel as Chief Business OfficerAugust 19, 2024 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest UpdateCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 100,700 shares, a decrease of 11.7% from the July 15th total of 114,000 shares. Based on an average daily trading volume, of 38,500 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.5% of the shares of the company are short sold.August 18, 2024 | marketbeat.comHC Wainwright & Co. Upgrades Cidara Therapeutics (CDTX)August 16, 2024 | msn.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Expected to Post Q1 2025 Earnings of ($4.66) Per ShareCidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cidara Therapeutics in a research note issued on Wednesday, August 14th. HC Wainwright analyst E. Arce forecasts that the biotechnology companAugust 15, 2024 | marketbeat.comCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | finanznachrichten.deCidara Therapeutics (NASDAQ:CDTX) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Cidara Therapeutics in a report on Wednesday.August 14, 2024 | marketbeat.comCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Shares Pass Below 50-Day Moving Average of $12.22Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below 50 Day Moving Average of $12.22August 13, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Rating of "Buy" from BrokeragesShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have received an average rating of "Buy" from the four ratings firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a buy rating and one has given a stroAugust 3, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Cross Above Fifty Day Moving Average of $12.27Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above 50 Day Moving Average of $12.27July 31, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average of $12.23Cidara Therapeutics (NASDAQ:CDTX) Stock Crosses Above 50-Day Moving Average of $12.23July 17, 2024 | marketbeat.comShort Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Rises By 5.8%Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 113,600 shares, an increase of 5.8% from the May 31st total of 107,400 shares. Currently, 2.6% of the shares of the company are sold short. Based on an average trading volume of 74,900 shares, the days-to-cover ratio is presently 1.5 days.July 3, 2024 | marketbeat.comCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3, 2024 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Cidara Therapeutics in a research note on Thursday.June 20, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Increase in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant increase in short interest in May. As of May 31st, there was short interest totalling 107,400 shares, an increase of 53.2% from the May 15th total of 70,100 shares. Approximately 2.5% of the shares of the stock are short sold. Based on an average daily volume of 70,600 shares, the days-to-cover ratio is presently 1.5 days.June 16, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by BrokeragesShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have earned an average recommendation of "Buy" from the four analysts that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a buy recommendation and one has given a strong buy rJune 14, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) CEO Purchases $105,680.00 in StockJune 12, 2024 | insidertrades.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest Down 16.2% in MayCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 70,100 shares, a decline of 16.2% from the April 30th total of 83,700 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average trading volume of 67,000 shares, the short-interest ratio is currently 1.0 days.June 2, 2024 | marketbeat.comCidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 ConferenceMay 30, 2024 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Shares Pass Below Fifty Day Moving Average of $14.59Cidara Therapeutics (NASDAQ:CDTX) Stock Passes Below Fifty Day Moving Average of $14.59May 29, 2024 | marketbeat.comBuy Rating Justified by Cidara Therapeutics’ Upcoming Clinical Trials and Expanding Oncology PipelineMay 16, 2024 | markets.businessinsider.comCidara Therapeutics, Inc.: Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 16, 2024 | finanznachrichten.deCidara Therapeutics (NASDAQ:CDTX) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $25.00 target price on shares of Cidara Therapeutics in a report on Thursday.May 16, 2024 | marketbeat.comCDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024May 16, 2024 | msn.comROSEN, A LEADING NATIONAL FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXMay 15, 2024 | stockhouse.comCidara Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | sfgate.comCidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 15, 2024 | globenewswire.com Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.480.41▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼32▲CDTX Articles Average Week Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SCYNEXIS News Today X4 Pharmaceuticals News Today Inhibrx News Today Nanobiotix News Today Kyverna Therapeutics News Today Solid Biosciences News Today Trevi Therapeutics News Today MacroGenics News Today XBiotech News Today Pyxis Oncology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
